Aktis Oncology (NASDAQ:AKTS) Issues Quarterly Earnings Results

Aktis Oncology (NASDAQ:AKTS) posted its quarterly earnings results on Thursday. The technology company reported ($0.44) EPS for the quarter, meeting the consensus estimate of ($0.44), reports. The business had revenue of $3.38 million during the quarter, compared to analysts’ expectations of $2.14 million.

Aktis Oncology Trading Down 0.9%

AKTS traded down $0.21 during trading on Thursday, hitting $23.79. The company’s stock had a trading volume of 156,314 shares, compared to its average volume of 339,958. The firm has a market capitalization of $1.27 billion and a price-to-earnings ratio of -62.61. Aktis Oncology has a twelve month low of $14.72 and a twelve month high of $34.19. The business’s fifty day simple moving average is $24.79 and its 200 day simple moving average is $21.11.

Analyst Ratings Changes

Several brokerages have recently issued reports on AKTS. Weiss Ratings raised Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. HC Wainwright upped their price objective on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. William Blair started coverage on shares of Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating for the company. Wall Street Zen cut shares of Aktis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Finally, Raymond James Financial began coverage on shares of Aktis Oncology in a research report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $34.60.

Insider Activity

In other news, Director Ken Herrmann sold 4,856 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $24.56, for a total transaction of $119,263.36. Following the transaction, the director owned 3,506 shares in the company, valued at $86,107.36. This trade represents a 58.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 3.30% of the stock is owned by company insiders.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.